Join Growin Stock Community!

Theravance biopharma, inc.TBPH.US Overview

US StockHealthcare
(No presentation for TBPH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TBPH AI Insights

TBPH Overall Performance

TBPH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TBPH Recent Performance

3.97%

Theravance biopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TBPH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TBPH Key Information

TBPH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TBPH Profile

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Price of TBPH

TBPH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TBPH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.58
PE Ratio (TTM)
32.02
Forward PE
-
PS Ratio (TTM)
11.51
PB Ratio
3.96
Price-to-FCF
3.94
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
36.53%
Revenue Growth (YoY)
27.12%
Profit Growth (YoY)
27.12%
3-Year Revenue Growth
17.09%
3-Year Profit Growth
17.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.58
PE Ratio (TTM)
32.02
Forward PE
-
PS Ratio (TTM)
11.51
PB Ratio
3.96
Price-to-FCF
3.94
Gross Margin
100.00%
Net Margin
36.53%
Revenue Growth (YoY)
27.12%
Profit Growth (YoY)
27.12%
3-Year Revenue Growth
17.09%
3-Year Profit Growth
17.09%

  • When is TBPH's latest earnings report released?

    The most recent financial report for Theravance biopharma, inc. (TBPH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TBPH's short-term business performance and financial health. For the latest updates on TBPH's earnings releases, visit this page regularly.

  • Where does TBPH fall in the P/E River chart?

    According to historical valuation range analysis, Theravance biopharma, inc. (TBPH)'s current price-to-earnings (P/E) ratio is 30.7, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of TBPH?

    According to the latest financial report, Theravance biopharma, inc. (TBPH) reported an Operating Profit of -6.46M with an Operating Margin of -32.29% this period, representing a growth of 40.44% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TBPH's revenue growth?

    In the latest financial report, Theravance biopharma, inc. (TBPH) announced revenue of 19.99M, with a Year-Over-Year growth rate of 18.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TBPH have?

    As of the end of the reporting period, Theravance biopharma, inc. (TBPH) had total debt of 44.6M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TBPH have?

    At the end of the period, Theravance biopharma, inc. (TBPH) held Total Cash and Cash Equivalents of 175.61M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does TBPH go with three margins increasing?

    In the latest report, Theravance biopharma, inc. (TBPH) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -32.29%%, and net margin of 18.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TBPH's profit trajectory and future growth potential.

  • Is TBPH's EPS continuing to grow?

    According to the past four quarterly reports, Theravance biopharma, inc. (TBPH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TBPH?

    Theravance biopharma, inc. (TBPH)'s Free Cash Flow (FCF) for the period is -6.51M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 24.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TBPH?

    The latest valuation data shows Theravance biopharma, inc. (TBPH) has a Price-To-Earnings (PE) ratio of 30.7 and a Price/Earnings-To-Growth (PEG) ratio of 0.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.